search icon
rare-img

Ultragenyx, Common Stock

RARE

NSQ

$35.03

+$0.68

(1.98%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.36B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.22M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.34
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$29.59 L
$60.37 H
$35.03

About Ultragenyx, Common Stock

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameRARESectorS&P500
1-Week Return-1.35%0.71%0.79%
1-Month Return-7.99%-5.6%6.04%
3-Month Return-18.38%-11.72%-1.11%
6-Month Return-26.45%-10.81%-2.39%
1-Year Return-8.15%-7.12%11.69%
3-Year Return-25.31%-0.57%42.29%
5-Year Return-48.83%27.64%93.12%
10-Year Return-59.74%75.45%179.21%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue271.03M351.41M363.33M434.25M560.23M[{"date":"2020-12-31","value":48.38,"profit":true},{"date":"2021-12-31","value":62.73,"profit":true},{"date":"2022-12-31","value":64.85,"profit":true},{"date":"2023-12-31","value":77.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue6.13M16.01M28.32M45.21M76.73M[{"date":"2020-12-31","value":7.99,"profit":true},{"date":"2021-12-31","value":20.86,"profit":true},{"date":"2022-12-31","value":36.91,"profit":true},{"date":"2023-12-31","value":58.92,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit264.90M335.40M335.01M389.04M483.50M[{"date":"2020-12-31","value":54.79,"profit":true},{"date":"2021-12-31","value":69.37,"profit":true},{"date":"2022-12-31","value":69.29,"profit":true},{"date":"2023-12-31","value":80.46,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin97.74%95.44%92.21%89.59%86.30%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.65,"profit":true},{"date":"2022-12-31","value":94.34,"profit":true},{"date":"2023-12-31","value":91.66,"profit":true},{"date":"2024-12-31","value":88.3,"profit":true}]
Operating Expenses595.02M717.13M983.93M958.25M1.02B[{"date":"2020-12-31","value":58.37,"profit":true},{"date":"2021-12-31","value":70.34,"profit":true},{"date":"2022-12-31","value":96.51,"profit":true},{"date":"2023-12-31","value":93.99,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(330.12M)(381.74M)(648.92M)(569.21M)(535.97M)[{"date":"2020-12-31","value":-33011600000,"profit":false},{"date":"2021-12-31","value":-38173700000,"profit":false},{"date":"2022-12-31","value":-64891900000,"profit":false},{"date":"2023-12-31","value":-56920800000,"profit":false},{"date":"2024-12-31","value":-53597300000,"profit":false}]
Total Non-Operating Income/Expense118.50M(100.67M)(84.75M)(78.57M)(58.15M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-84.95,"profit":false},{"date":"2022-12-31","value":-71.51,"profit":false},{"date":"2023-12-31","value":-66.3,"profit":false},{"date":"2024-12-31","value":-49.07,"profit":false}]
Pre-Tax Income(185.36M)(452.98M)(701.73M)(608.46M)(567.59M)[{"date":"2020-12-31","value":-18535900000,"profit":false},{"date":"2021-12-31","value":-45298100000,"profit":false},{"date":"2022-12-31","value":-70172500000,"profit":false},{"date":"2023-12-31","value":-60846400000,"profit":false},{"date":"2024-12-31","value":-56758600000,"profit":false}]
Income Taxes1.21M1.04M5.70M(1.82M)1.60M[{"date":"2020-12-31","value":21.19,"profit":true},{"date":"2021-12-31","value":18.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-32.04,"profit":false},{"date":"2024-12-31","value":28.04,"profit":true}]
Income After Taxes(186.57M)(454.02M)(707.42M)(606.64M)(569.18M)[{"date":"2020-12-31","value":-18656600000,"profit":false},{"date":"2021-12-31","value":-45402500000,"profit":false},{"date":"2022-12-31","value":-70742100000,"profit":false},{"date":"2023-12-31","value":-60663900000,"profit":false},{"date":"2024-12-31","value":-56918300000,"profit":false}]
Income From Continuous Operations(186.57M)(454.02M)(707.42M)(606.64M)(569.18M)[{"date":"2020-12-31","value":-18656600000,"profit":false},{"date":"2021-12-31","value":-45402500000,"profit":false},{"date":"2022-12-31","value":-70742100000,"profit":false},{"date":"2023-12-31","value":-60663900000,"profit":false},{"date":"2024-12-31","value":-56918300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(186.57M)(454.02M)(707.42M)(606.64M)(569.18M)[{"date":"2020-12-31","value":-18656600000,"profit":false},{"date":"2021-12-31","value":-45402500000,"profit":false},{"date":"2022-12-31","value":-70742100000,"profit":false},{"date":"2023-12-31","value":-60663900000,"profit":false},{"date":"2024-12-31","value":-56918300000,"profit":false}]
EPS (Diluted)(3.00)(6.71)(10.11)(8.33)(6.34)[{"date":"2020-12-31","value":-300,"profit":false},{"date":"2021-12-31","value":-671,"profit":false},{"date":"2022-12-31","value":-1011,"profit":false},{"date":"2023-12-31","value":-833,"profit":false},{"date":"2024-12-31","value":-634,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RARE
Cash Ratio 1.70
Current Ratio 2.40
Quick Ratio 2.24

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RARE
ROA (LTM) -24.51%
ROE (LTM) -377.06%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RARE
Debt Ratio Lower is generally better. Negative is bad. 0.88
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.11

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RARE
Trailing PE NM
Forward PE NM
P/S (TTM) 5.61
P/B 22.96
Price/FCF NM
EV/R 4.83
EV/Ebitda NM
PEG NM

FAQs

What is Ultragenyx share price today?

Ultragenyx (RARE) share price today is $35.03

Can Indians buy Ultragenyx shares?

Yes, Indians can buy shares of Ultragenyx (RARE) on Vested. To buy Ultragenyx from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RARE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Ultragenyx be purchased?

Yes, you can purchase fractional shares of Ultragenyx (RARE) via the Vested app. You can start investing in Ultragenyx (RARE) with a minimum investment of $1.

How to invest in Ultragenyx shares from India?

You can invest in shares of Ultragenyx (RARE) via Vested in three simple steps:

  • Click on Sign Up or Invest in RARE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Ultragenyx shares
What is Ultragenyx 52-week high and low stock price?

The 52-week high price of Ultragenyx (RARE) is $60.37. The 52-week low price of Ultragenyx (RARE) is $29.59.

What is Ultragenyx price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Ultragenyx (RARE) is 22.96

What is the Market Cap of Ultragenyx?

The market capitalization of Ultragenyx (RARE) is $3.36B

What is Ultragenyx’s stock symbol?

The stock symbol (or ticker) of Ultragenyx is RARE

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top